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Commentary
The Challenges of Prioritization
Anne Mills*
London School of Hygiene & Tropical Medicine, London, UK
As an economist, acceptance of the need for prioritization and
of the value of systematic thinking about and analysis of prior-
ities is fundamental to my thinking about resource allocation
to health and within the health system. However, this does not
mean that I believe that economic tools for evaluating priori-
ties should necessarily dictate policy decisions. Prioritization
is a political and ethical process as well as a technical one.
In addition, economic tools such as cost-effectiveness and
cost–benefit analysis have their limitations when it comes to
encompassing the range of types of decisions needing to be
evaluated to guide resource allocation. A particular concern
of mine is that the analytical method should not excessively
drive the nature of the issues being prioritized for resources.
Cost-effectiveness analysis has traditionally been applied
primarily to very specific interventions, such as drugs and
diagnostics; in addition, the evidence base drawn on for eval-
uating such interventions is relatively good, given the medical
research industry surrounding their testing. However, with
increasing success in controlling infectious diseases, many of
the health challenges facing countries concern broad threats
to health with multiple causes, such as obesity, where the
relationship between policy action and health benefit is not
well researched or understood. In addition, benefits of policy
action are not necessarily confined to health, with broader
effects both on general well-being and across different sec-
tors. Both the evidence base of the link between inputs and
outputs and the conceptualization of relevant costs and bene-
fits present far more challenges to analysts.
Health decision makers need to prioritize not just a bene-
fits package of specific interventions but also broader public
health packages and public health systems—such as surveil-
lance—that cannot easily be evaluated within standard prior-
ity-setting approaches. Greater attention needs to be paid to
how best to do this, in order to avoid further accentuating the
medicalization of our health systems.
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